NasdaqGS - Delayed Quote • USD
Incyte Corporation (INCY)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:53 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 17 | 18 |
| Avg. Estimate | 0.85 | 1.15 | 4.48 | 5.3 |
| Low Estimate | 0.55 | 0.99 | 3.59 | 3.61 |
| High Estimate | 1.06 | 1.25 | 5.8 | 6.88 |
| Year Ago EPS | 0.37 | 0.99 | 3.52 | 4.48 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 16 | 19 | 19 |
| Avg. Estimate | 926.88M | 1.03B | 4.13B | 4.57B |
| Low Estimate | 880.3M | 994.1M | 3.99B | 4.18B |
| High Estimate | 990M | 1.07B | 4.26B | 4.78B |
| Year Ago Sales | 859.17M | 954.61M | 3.7B | 4.13B |
| Sales Growth (year/est) | 7.90% | 7.50% | 11.80% | 10.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.75 | 0.83 | 1.02 | 1.16 |
| EPS Actual | 0.37 | 0.99 | 1.1 | 1.06 |
| Difference | -0.38 | 0.16 | 0.08 | -0.1 |
| Surprise % | -50.70% | 19.30% | 7.80% | -8.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.85 | 1.15 | 4.48 | 5.3 |
| 7 Days Ago | 0.89 | 1.16 | 4.55 | 5.4 |
| 30 Days Ago | 0.87 | 1.16 | 4.58 | 5.46 |
| 60 Days Ago | 0.87 | 1.17 | 4.59 | 5.47 |
| 90 Days Ago | 0.87 | 1.12 | 4.51 | 5.49 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 4 | 3 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 2 | 3 | 2 |
Growth Estimates
| CURRENCY IN USD | INCY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 129.70% | -- | -- | 6.50% |
| Next Qtr. | 16.20% | -- | -- | 12.00% |
| Current Year | 27.30% | -- | -- | 5.30% |
| Next Year | 18.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 22.50% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 4.86% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Oppenheimer: Outperform to Outperform | 4/24/2024 |
| Initiated | Cantor Fitzgerald: Neutral | 4/23/2024 |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/25/2024 |
| Maintains | B of A Securities: Neutral to Neutral | 3/13/2024 |
| Reiterates | Stifel: Hold to Hold | 3/12/2024 |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/12/2024 |
Related Tickers
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%
JAZZ Jazz Pharmaceuticals plc
109.46
+1.89%
ALNY Alnylam Pharmaceuticals, Inc.
143.31
-0.28%
EXEL Exelixis, Inc.
23.70
+0.72%
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
LEGN Legend Biotech Corporation
45.30
+1.98%
GMAB Genmab A/S
28.15
+2.51%
GERN Geron Corporation
3.7900
+6.46%
ARGX argenx SE
372.80
+1.14%
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%